A Phase 2 study of Obe-cel in Severe, Refractory Systemic Lupus Erythematosus (SLE) with Active Lupus Nephritis (LN)
Study Title:
A Phase 2 study of Obe-cel in Severe, Refractory Systemic Lupus Erythematosus (SLE) with Active Lupus Nephritis (LN)
Sponsor Name:
Autolus Ltd
Purpose of Study:
Treatments specifically for lupus-related kidney disease (lupus nephritis) have been approved in recent years and are often used with standard therapies. Yet durable long-term remission is still hard to reach, especially in those with refractory SLE (lupus that doesn't respond well to standard treatment).
This study evaluates obe-cel, an investigational cell therapy, in people with refractory SLE with LN. Its main goals are to assess:
- Efficacy: Whether obe-cel can help people with refractory SLE with active LN achieve complete renal response (CRR), meaning that their kidney disease is in remission, at 6 months post-infusion without needing rescue medication.
- Safety and pharmacokinetics: How safe obe-cel is, and how it behaves in the body, in people with refractory SLE with active LN.
What Does this Study Involve?
Participation in the study lasts at minimum 2 years with option for a 15-year follow-up period, and includes:
- Screening (about 4-5 weeks): Participants will discuss consent with the study team and complete a physical exam, blood and urine tests (including a 24-hour urine collection), heart tests, infection screening, and a review of a recent or new kidney biopsy to confirm active lupus nephritis.
- Treatment period: Once screening is complete, participants will undergo leukapheresis, a procedure that collects your own T cells so they can be made into your personalized study treatment through cell engineering (obe-cel). You'll then receive a short course of pretreatment with fludarabine and cyclophosphamide to prepare your body. This process clears out your existing immune cells to make room for and create a favorable immune environment for engineered T cells. This process will be followed by a single infusion of obe-cel.
Post-treatment period: Participants will stay in the hospital for at least 7 days so the study team can monitor you closely and remain near the hospital through Day 28 for additional visits and safety checks. After discharge, you'll check your temperature at home and should avoid driving for at least 2 weeks.
Visits then continue monthly for a year, then every 6 months for at least 2 years total, and include exams, questionnaires, blood work, and 24-hour urine collections.
Most other lupus immunosuppressants must be paused during the study, though limited steroids may be allowed for flares.
To Consider Participation in This Study, You Must:
- Be between 12 and 65 years old
- Be diagnosed with systemic lupus erythematosus (SLE) according to 2019 EULAR/ACR criteria
- Test positive for at least 1 autoantibody, as defined by the study protocol
- Have severe, active SLE that hasn’t responded to standard-of-care treatment
- Have biopsy-confirmed severe, active LN— a kidney biopsy is required during the study or within 6 months prior to participation to confirm ongoing active class III, IV, or V (only in combination with class III or IV) and active or active/chronic LN
If you have any of the following, you will not be able to participate:
- End-stage renal disease (on dialysis, or creatinine clearance below the study threshold)
- Severe active neuropsychiatric SLE (severe CNS lupus, active psychosis, or a poorly controlled seizure disorder)
- Active or uncontrolled infection (HIV, active hepatitis B or C, or a history of active TB)
- Active cancer, or a cancer history within a defined period
- Prior CAR-T cell therapy or gene therapy
- Planning pregnancy or breastfeeding (without adequate contraception)
- Significant heart or lung conditions that would raise the risk of lymphodepleting chemotherapy or CAR-T infusion
- A new or changed dose of a RAAS inhibitor or SGLT2 inhibitor within 2 weeks of screening
Additional inclusion/exclusion criteria may apply and will be discussed with you by the study team.
Learn More
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. If you are a person living with lupus and you want to learn more about clinical trials and other research opportunities that may be right for you, sign up for the Lupus Foundation of America’s Research Accelerated by You (RAY®).
Already part of RAY? To stay connected, reactivate your account today at ray.lupus.org. Sign in with the email linked to your RAY account, update your password, verify your email, and review your profile and consent form.
Need help? We're here at RAYcoordinator@lupus.org.